Gap Between Sun Pharma’s Price And Analyst Target Widest In 15 Months
The gap between share price of India's largest drugmaker and the analysts' target price is at its widest in 15 months after the stock slumped nearly 8 percent on Monday.
The difference between stock price of Sun Pharmaceutical Industries Ltd. and its 12-month consensus target rose to more than 28 percent, the most since August 2017, according to Bloomberg data.
Sun Pharma tumbled as much as 13.21 percent, the most in a year and a half, yesterday on a report that the market regulator may reopen its probe into an insider trading case against the company and alleged lapses by some of its promoters. With this, the stock has declined more than 21 percent in 2018, making it the second-worst performer on the Nifty.
Edelweiss cut its target price for the stock to Rs 430 apiece, implying a potential downside of 5.5 percent from the last regular trade. The research firm has sought more clarity on Sun Pharma's domestic business being routed via a third party, Aditya Medisales, and its unsecured loans. Unless the company re-evaluates some of its structures and transactions, Edelweiss said, these issues will overshadow its overall performance.
Watch the video here:
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
